Myriad Genetics Inc (MYGN):製薬・医療:M&Aディール及び事業提携情報

GlobalDataが発行した調査報告書(DATA904C10094)
◆英語タイトル:Myriad Genetics Inc (MYGN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10094
◆発行会社(リサーチ会社):GlobalData
◆発行日:2018年11月
◆ページ数:58
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥26,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥52,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥78,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Myriad Genetics Inc (Myriad) is a specialty molecular diagnostic company, which discovers and commercializes molecular diagnostic tests, personalized medicine and services for major diseases. The company’s product portfolio includes molecular diagnostic testing products that analyze genes, their expression levels and corresponding proteins to assess a person risk for developing disease later in life, accurately diagnose disease and determine a patient’s likelihood of responding to a particular drug. It also provides an array of pharmaceutical and clinical services. Myriad markets its products through its sales force in Europe and Canada and through distributor agreements in Latin American, Middle Eastern, Asian and African countries. The company has operations in the US, Spain, France, Switzerland, the UK, Canada, the Netherlands and Italy. Myriad is headquartered in Salt Lake City, Utah, the US.

Myriad Genetics Inc (MYGN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Myriad Genetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Myriad Genetics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Myriad Genetics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Myriad Genetics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Myriad Genetics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Myriad Genetics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Myriad Genetics Inc, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
Myriad Genetics to Raise Funds through Venture Financing 13
AssureRx Health Raises Additional USD15 Million in Series D Financing 14
AssureRx Health Raises USD30 Million in Venture Financing Round 15
Assurex Health Raises USD30 Million in Venture Financing 17
AssureRx Health Raises USD7 Million in Venture Financing 18
RainDance Technologies Raises US$20 Million In Series E Financing 20
Counsyl Secures USD7.5 Million in Series C Funding 22
Assurex Health Secures USD12.5 Million in Series C Funding Round 23
AssureRx Health Raises US$12.5 Million In Series C Financing 24
Counsyl Secures USD34 Million in Series B Round of Funding 26
Assurex Health Secures USD8 Million in Venture Funding Round 27
Private Equity 28
Perceptive Advisors Invests USD80 Million in Counsyl 28
Partnerships 29
Myriad Genetics and Pfizer Enter into Agreement 29
Myriad Genetics Enters into Development Agreement with Beigene 30
Myriad Enters into Agreement with Sanofi 31
Myriad Genetics Expands Research Agreement with AbbVie for Veliparib 32
Myriad Genetics Enters into Research Agreement with Tesaro and Merck 33
Centre for Addiction and Mental Health And AssureRx Health Form Joint Venture 34
Myriad Genetics Expands Research Agreement with AbbVie 35
Acquisition 36
Myriad Genetics Acquires Assurex Health for USD351.6 Million 36
Myriad Genetics Acquires Privatklinik Dr. Robert Schindlbeck for USD20.1 Million 38
Myriad Genetics Inc – Key Competitors 39
Myriad Genetics Inc – Key Employees 40
Myriad Genetics Inc – Locations And Subsidiaries 41
Head Office 41
Other Locations & Subsidiaries 41
Recent Developments 43
Financial Announcements 43
Aug 21, 2018: Myriad Genetics reports fiscal fourth-quarter and full-year 2018 financial results 43
May 08, 2018: Myriad Genetics Reports Fiscal Third-Quarter 2018 Financial Results 46
Feb 06, 2018: Myriad Genetics Reports Fiscal Second-Quarter 2018 Financial Results 48
Nov 07, 2017: Myriad Genetics Reports Fiscal First-Quarter 2018 Financial Results 50
Aug 08, 2017: Myriad Genetics Reports Fiscal Fourth-Quarter 2017 and Fiscal Full-Year 2017 Financial Results 51
May 02, 2017: Myriad Genetics Reports Fiscal Third-Quarter 2017 Financial Results 52
Feb 07, 2017: Myriad Genetics Reports Fiscal Second-Quarter 2017 Financial Results 54
Legal and Regulatory 56
Apr 23, 2018: Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against  Myriad Genetics, Inc. 56
Government and Public Interest 57
Jan 22, 2018: Myriad Applauds New Consensus Statement From International Expert Panel On Screening Recommendations for Hereditary Prostate Cancer 57
Appendix 58
Methodology 58
About GlobalData 58
Contact Us 58
Disclaimer 58

List of Tables
Myriad Genetics Inc, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Myriad Genetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Myriad Genetics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Myriad Genetics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Myriad Genetics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Myriad Genetics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Myriad Genetics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Myriad Genetics to Raise Funds through Venture Financing 13
AssureRx Health Raises Additional USD15 Million in Series D Financing 14
AssureRx Health Raises USD30 Million in Venture Financing Round 15
Assurex Health Raises USD30 Million in Venture Financing 17
AssureRx Health Raises USD7 Million in Venture Financing 18
RainDance Technologies Raises US$20 Million In Series E Financing 20
Counsyl Secures USD7.5 Million in Series C Funding 22
Assurex Health Secures USD12.5 Million in Series C Funding Round 23
AssureRx Health Raises US$12.5 Million In Series C Financing 24
Counsyl Secures USD34 Million in Series B Round of Funding 26
Assurex Health Secures USD8 Million in Venture Funding Round 27
Perceptive Advisors Invests USD80 Million in Counsyl 28
Myriad Genetics and Pfizer Enter into Agreement 29
Myriad Genetics Enters into Development Agreement with Beigene 30
Myriad Enters into Agreement with Sanofi 31
Myriad Genetics Expands Research Agreement with AbbVie for Veliparib 32
Myriad Genetics Enters into Research Agreement with Tesaro and Merck 33
Centre for Addiction and Mental Health And AssureRx Health Form Joint Venture 34
Myriad Genetics Expands Research Agreement with AbbVie 35
Myriad Genetics Acquires Assurex Health for USD351.6 Million 36
Myriad Genetics Acquires Privatklinik Dr. Robert Schindlbeck for USD20.1 Million 38
Myriad Genetics Inc, Key Competitors 39
Myriad Genetics Inc, Key Employees 40
Myriad Genetics Inc, Subsidiaries 41

List of Figures
Myriad Genetics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Myriad Genetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Myriad Genetics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Myriad Genetics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Myriad Genetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Myriad Genetics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Myriad Genetics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Myriad Genetics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Myriad Genetics Inc, Medical Devices Deals, 2012 to YTD 2018 10

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Myriad Genetics Inc (MYGN):製薬・医療:M&Aディール及び事業提携情報(Myriad Genetics Inc (MYGN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆